Form 4 for KRYS Krystal Biotech, Inc.
Accepted 2025-07-11 00:00:00 ET · period of report 2025-07-09 · accession 0001298709-25-000007 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| MI | 2025-07-11 | 2025-07-09+ | KRYS | Krishnan Krish S | Pres, CEO, Dir, 10% | S - Sale | $150.28 | -7,000 | 1.46M | -0.5% | -$1.05M |
| M | 2025-07-11 | 2025-07-09+ | KRYS | Krishnan Krish S | Pres, CEO, Dir, 10% | S - Sale | $150.27 | -7,127 | 1.53M | -0.5% | -$1.07M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-07-10 | S | D | 6,500 | $150.23 | 1,457,011 | I | — | — | (F6) The sales reported were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person's spouse, Suma M. Krishnan, that started on September 12, 2024 and will terminate on September 13, 2025. (F3) The transaction was executed in multiple trades ranging from $150.00 to $150.8500. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. |
| 2 | Common | Common Stock | 2025-07-09 | S | D | 200 | $150.14 | 1,463,511 | I | — | — | (F6) The sales reported were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person's spouse, Suma M. Krishnan, that started on September 12, 2024 and will terminate on September 13, 2025. (F7) The transaction was executed in multiple trades ranging from $150.1200 to $150.1600. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. |
| 3 | Common | Common Stock | 2025-07-10 | S | D | 300 | $151.39 | 1,525,929 | D By Spouse | — | — | (F1) The sales reported were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person that started on September 12, 2024 and will terminate on September 13, 2025 . (F4) The transaction was executed in three trades of 100 shares each at $151.350, $151.40, and $151.41, respectively. The price reported above reflects the average sale price. (F8) Directly beneficially owned by Suma M. Krishnan, the spouse of the Reporting Person. |
| 4 | Common | Common Stock | 2025-07-10 | S | D | 6,627 | $150.22 | 1,526,229 | D By Spouse | — | — | (F1) The sales reported were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person that started on September 12, 2024 and will terminate on September 13, 2025 . (F3) The transaction was executed in multiple trades ranging from $150.00 to $150.8500. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. (F8) Directly beneficially owned by Suma M. Krishnan, the spouse of the Reporting Person. |
| 5 | Common | Common Stock | 2025-07-09 | S | D | 200 | $150.07 | 1,532,856 | D By Spouse | — | — | (F1) The sales reported were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person that started on September 12, 2024 and will terminate on September 13, 2025 . (F2) The transaction was executed in two trades of 100 shares each at $150 and $150.14, respectively. The price reported above reflects the average sale price. (F8) Directly beneficially owned by Suma M. Krishnan, the spouse of the Reporting Person. |
| 6 | Common | Common Stock | 2025-07-10 | S | D | 300 | $151.39 | 1,456,711 | I | — | — | (F6) The sales reported were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person's spouse, Suma M. Krishnan, that started on September 12, 2024 and will terminate on September 13, 2025. (F4) The transaction was executed in three trades of 100 shares each at $151.350, $151.40, and $151.41, respectively. The price reported above reflects the average sale price. |